A Two-part, Open-label Phase 1/2 Study to Evaluate Pharmacodynamic Effects and Safety of Olaptesed Pegol Monotherapy and Safety and Efficacy of Olaptesed Pegol / Pembrolizumab Combination Therapy in Metastatic Colorectal and Pancreatic Cancer
Phase of Trial: Phase I/II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Olaptesed pegol (Primary) ; Pembrolizumab (Primary)
- Indications Colorectal cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Pharmacodynamics
- Acronyms Keynote-559; OPERA
- Sponsors NOXXON Pharma AG
- 13 Mar 2018 According to a NOXXON Pharma AG media release, top-line data is expected in 2018.
- 06 Apr 2017 Status changed from planning to recruiting.
- 23 Dec 2016 New trial record